Open-label study to assess how the pharmacokinetics (i.e. the way the body absorbs, distributes and gets rid of a drug), safety, and tolerability of the drug siponimod are influenced by the presence of specific genetic characteristics (namely CYP2C9 genotypes).

Exclusion Criteria8

• Subjects with CYP2C9 *1/*2, *2/*2, and *1/*3 genotypes according to screening results.
• Clinically significant disease of any major system organ class including (but not limited to) cardiovascular, metabolic, renal, neurological or psychiatric diseases which has not resolved within two weeks prior to initial dosing.
• History or presence (=screening or first baseline) of any clinically significant ECG abnormalities.
• Any clinically significant laboratory abnormalities at screening that may jeopardize the subjects' safety throughout the study (as judged by the investigator).
• Smokers as defined by reported tobacco use or urine cotinine concentrations greater than or equal to 500 ng/mL at screening or baseline visit.
• Use of any prescription drug, herbal drug or over-the-counter medication from four weeks prior to initial dosing.
• Pregnant or nursing (lactating) females.
• Any surgical or medical condition which, as judged by the investigator, might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.